Description of Research Expertise
Dr. Aggarwal is the Leslye Heisler Associate Professor for Lung Cancer Excellence at the University of Pennsylvania’s Perelman School of Medicine.
Dr. Aggarwal specializes in the management of patients with lung cancer, with a specific and clinical research focus on the development of personalized therapeutic approaches, and the discovery and application of biomarkers to guide treatment. She is a world-renowned expert in the application of plasma-based gene sequencing in the management of patients with metastatic lung cancer, and is actively working on implementation of comprehensive testing, and discovery of approaches focusing on early detection, detection of resistance mutations and disease monitoring.
Dr. Aggarwal serves as the Associate Director of Penn Center for Precision Medicine, and Director of Precision Medicine Innovation at the Penn Center for Cancer Care Innovation (PC3I). In her roles, she is actively involved in developing, implementing, and advancing strategic and operational precision medicine initiatives with a focus on those that involve bringing new technologies or approaches to clinical care and ultimately deliver on the promise of personalized cancer therapy.
She is an active member of the Abramson Cancer Center where she serves as Physician Leader for the clinical research program for Airways Malignancies. Dr. Aggarwal performs patient-centered, scientifically relevant novel immunotherapy clinical trials that will make a tangible impact and advance our understanding of immunotherapy in patients with Lung Cancer.
Selected Publications
Aggarwal C, Liu SV.: Zipalertinib in EGFR Exon 20-Mutant Non-Small-Cell Lung Cancer: Drug Development in a Rare but Crowded Setting. J Clin Oncol. 41 (26): 4200-4203,2023.
Yegya-Raman N, Friedes C, Lee SH, Iocolano M, Duan L, Wang X, Li B, Aggarwal C, Cohen RB, Su W, Doucette A, Levin WP, Cengel KA, DiBardino D, Teo BK, O'Reilly SE, Sun L, Bradley JD, Xiao Y, Langer CJ, Feigenberg SJ.: Pneumonitis rates before and after adoption of immunotherapy consolidation in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiation. Int J Radiat Oncol Biol Phys. S0360-3016 (23): 07815-X,2023.
Sun L, Bleiberg B, Hwang WT, Marmarelis ME, Langer CJ, Singh A, Cohen RB, Mamtani R, Aggarwal C.: Association Between Duration of Immunotherapy and Overall Survival in Advanced Non-Small Cell Lung Cancer JAMA Oncol. 9 (8): 1075-1082.,2023.
Yegya-Raman N, Berman AT, Ciunci CA, Friedes C, Berlin E, Iocolano M, Wang X, Lai C, Levin WP, Cengel KA, O'Reilly SE, Cohen RB, Aggarwal C, Marmarelis ME, Singh AP, Sun L, Bradley JD, Plastaras JP, Simone CB 2nd, Langer CJ, Feigenberg SJ: Phase II trial of consolidation pembrolizumab after proton reirradiation for thoracic recurrences of non-small cell lung cancer: Pembro after PBT ReRT for NSCLC. Int J Radiat Oncol Biol Phys. 29:S0360-3016 (23): 07846-X,2023.
Aggarwal C, Gong M, Kumar R.: MEDI0457 Plus Durvalumab in HPV-associated HNSCC-Response.
Clin Cancer Res. 29 (14): 2736,2023.
Gutierrez M, Lam WS, Hellmann MD, Gubens MA, Aggarwal C, Tan DSW, Felip E, Chiu JWY, Lee JS, Yang JC, Garon EB, Finocchiaro G, Ahn MJ, Luft A, Landers GA, Basso A, Ma H, Kobie J, Palcza J, Cristescu R, Fong L, Snyder A, Yuan J, Herbst RS.: Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results. Nat Med. 29 (7): 1718-1727,2023.
Yegya-Raman N, Friedes C, Sun L, Iocolano M, Kim KN, Doucette A, Cohen RB, Robinson KW, Levin WP, Cengel KA, Lally B, Agarwal M, D'Avella CA, Marmarelis ME, Kosteva JA, Singh AP, Ciunci CA, Aggarwal C, Berman AT, Langer CJ, Feigenberg SJ.: Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System. Clin Lung Cancer 24 (5): 474-482.,2023.
Tompkins WP, Hwang WT, Yang YX, Singh A, Ciunci C, D'Avella C, Aggarwal C, Cohen RB, Langer CJ, Mamtani R, Marmarelis ME: Brief Report: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimens.
Clin Lung Cancer. 24 (6): 558-562.e2. ,2023.
Aggarwal C, West HJ.: Molecular Marker Testing in Curable Non-Small Cell Lung Cancer-Practice Necessarily Precedes Data. JAMA Oncology 9 (6): 758-760,2023.
Simone CB, Yegya-Raman N, Manjunath S, Verma V, Shabason JE, Xu L, Cengel KA, Levin WP, Berman AT, Christodouleas JP, Aggarwal C, Cohen RB, Langer CJ, Pechet TT, Singal S, Kucharczuk JC, Rengan R, Feigenberg SJ.: Prospective Feasibility and Phase I/II Trial of Preoperative Proton Beam Therapy with Concurrent Chemotherapy for Resectable Stage IIIA or Superior Sulcus Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. S0360-3016 (23): 00463-7,2023.
Academic Contact Information
Perelman Center for Advanced Medicine
10-137, South Pavilion
3400 Civic Center Boulevard
Philadelphia,
PA
19104
Phone: 215-662-6318
Patient appointments: 800-789-7366